Antares Pharma, Inc. (ATRS) Analysts See $-0.02 EPS

July 14, 2018 - By Christine McCrea

Investors sentiment decreased to 0.8 in Q1 2018. Its down 0.36, from 1.16 in 2017Q4. It fall, as 15 investors sold Antares Pharma, Inc. shares while 26 reduced holdings. 10 funds opened positions while 23 raised stakes. 55.98 million shares or 2.75% more from 54.49 million shares in 2017Q4 were reported.
Amer holds 91,853 shares. Veritable Ltd Partnership reported 100,000 shares or 0% of all its holdings. Panagora Asset Mgmt Incorporated holds 0.01% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 1.30M shares. Legal & General Grp Pcl invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Element Cap Mngmt Ltd reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Bluecrest Mgmt Ltd holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 14,019 shares. The Washington-based Parametric Portfolio Associate Ltd Liability Com has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Morgan Stanley holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 664,736 shares. Goldman Sachs Grp has invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Armistice Capital Limited Liability Corporation holds 12.56 million shares. Royal Bancorp Of Canada holds 0% in Antares Pharma, Inc. (NASDAQ:ATRS) or 13,796 shares. Metropolitan Life Insur Ny, a New York-based fund reported 22,737 shares. Blackrock has 9.14M shares. Bnp Paribas Arbitrage reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). 805,200 were accumulated by California Employees Retirement Systems.

Since May 9, 2018, it had 0 buys, and 11 sales for $4.59 million activity.

Analysts expect Antares Pharma, Inc. (NASDAQ:ATRS) to report $-0.02 EPS on August, 14.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.02 EPS. After having $-0.04 EPS previously, Antares Pharma, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 0.74% or $0.02 during the last trading session, reaching $2.69. About 415,674 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has declined 4.71% since July 14, 2017 and is downtrending. It has underperformed by 17.28% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $421.86 million. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More news for Antares Pharma, Inc. (NASDAQ:ATRS) were recently published by: Benzinga.com, which released: “28 Stocks Moving In Thursday’s Pre-Market Session” on July 05, 2018. Seekingalpha.com‘s article titled: “Swinging For The Fence On Antares Pharma” and published on July 08, 2018 is yet another important article.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: